ArticleBMC medical genomics2025
CUX1 variant and 9p deletion: expanding the spectrum and resolving variable GDD/ID in a family.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIntellectual disability (ID) significantly impacts individual development and imposes a societal burden. Although mild ID accounts for approximately 85% of total cases, research into its genetic etiology remains relatively limited. We investigated a two-generation pedigree exhibiting varying degrees of global developmental delay (GDD) and ID. We collected clinical data from the proband and her parents, identified the genetic etiology through testing, investigated pathogenic mechanisms, and provided family genetic counseling.
methodsPeripheral blood samples were collected from pedigree members for chromosomal karyotyping and genomic DNA extraction. Trio exome sequencing (Trio-ES) was performed on the DNA samples. Candidate variants identified were validated using Sanger sequencing, and their pathogenicity was assessed in accordance with the standards and guidelines of the American College of Medical Genetics and Genomics (ACMG).
resultsThe proband, a 2-year-old female, presented with GDD. Her father exhibited borderline intellectual disability, while her mother had mild intellectual disability. ES analysis revealed: Exome sequencing identified a unknown inheritance heterozygous variant (NM_001202543.2[CUX1]: c.2637G > A [p.Trp879*]) in both the proband and her father, classified as likely pathogenic. The mother carried an 8.60 Mb deletion (seq[hg19]del(9)(p24.3p24.1), which was classified as a pathogenic copy number variant (CNV).
conclusionOur findings expand the spectrum of genetic variations associated with CUX1-related disorders. The conclusive molecular diagnosis established through genetic testing not only facilitated accurate genetic counseling but also reduced the time and economic burdens associated with the diagnostic odyssey.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.